U.S. Stock Night Market Opening Movements
Canopy Growth rose 12.07% in the night market. Based on recent key news:
<ol>
<li>
On December 13, market expectations for Trump to soon sign an executive order reclassifying cannabis drove cannabis stocks up. Canopy Growth's stock price rose over 12%, as the policy change could attract more investment and improve banking services. Source: MarketWatch
</li>
<li>
On December 12, technical analysis showed that Canopy Growth formed a bullish divergence, indicating that the stock price might break through resistance levels. The price increase reflects market expectations for reclassification. Source: Invezz
</li>
<li>
On December 13, the successful launch of Tilray products boosted the overall cannabis industry. Canopy Growth benefited from industry optimism, with its stock price significantly rising. Source: MarketWatch. Policy changes in the cannabis industry have sparked an investment frenzy.
</li>
</ol>
Barclays rose 3.69% in the night market. Based on recent key news:
<ol>
<li>
On December 12, despite weak macroeconomic data from the UK, strong gains in bank and mining stocks boosted the FTSE 100 index. Barclays' stock price rose 1.4%, with market expectations for the Bank of England to cut interest rates in 2026 helping to maintain upward momentum in the stock market. (Financial Associated Press)
</li>
<li>
On December 12, the Federal Reserve's bond purchase scale exceeded expectations, driving down borrowing costs. Barclays estimates that the Fed's final purchases of short-term U.S. Treasury bonds in 2026 could approach $525 billion, significantly higher than the previous forecast of $345 billion. (Jin10)
</li>
<li>
On December 12, Barclays continued to hold trading ideas for U.S. Treasury bonds, expecting yields to decline. Strategists believe the market should focus more on the labor market rather than policy rates. (WSJ) Bank stocks rose despite weak macro data.
</li>
</ol>
Top Gainers in the U.S. Stock Night Market
Kyverna Therapeutics rose 17.54% in the night market. Based on recent key news:
<ol>
<li>
On December 15, Kyverna Therapeutics announced it would release the topline results of the KYSA-8 clinical trial. This trial evaluates the effects of KYV-101 in patients with Stiff Person Syndrome. This news attracted market attention, driving the stock price up 17.54%. Data source: Company official announcement.
</li>
<li>
On December 14, the company planned to hold a live webcast and conference call on December 15 to present key presentations and insights to investors and stakeholders. This event attracted investor interest, further driving the stock price up. Data source: Company official announcement.
</li>
<li>
No other significant news recently. The biotechnology sector has been active lately, with noticeable capital inflows.
</li>
</ol>
TNL Mediagene rose 16.72% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, this stock shows significant volatility, and specific reasons need further observation
Tilray rose 13.00% in after-hours trading. Based on recent news,
<ol>
<li>
On December 13, Trump is set to sign an executive order to reclassify cannabis, causing Tilray's stock price to soar. This policy will attract more investment and improve banking services, with Tilray's stock price rising over 28%;
</li>
<li>
On December 12, Tilray announced the launch of a new Amped Live Resin Liquid Diamond 1g 510 cartridges product line, receiving a positive market response and an increase in stock price;
</li>
<li>
On December 12, U.S. stock market capital flows warmed up, benefiting Tilray from the overall improvement in market sentiment, leading to a rise in stock price. Changes in cannabis industry policies and improved market sentiment
</li>
</ol>

Canopy Growth rose 12.07% in after-hours trading; Barclays rose 3.69% in after-hours trading; Kyverna Therapeutics rose 17.54% in after-hours trading; TNL Mediagene rose 16.72% in after-hours trading; Tilray rose 13.00% in after-hours trading

U.S. stock night trading opens with fluctuations: Canopy Growth rises 12.07% in night trading; Barclays rises 3.69% in night trading